Shareholders Equity: The sum of preferred and common equity items.
Lixte Biotechnology Holdings, Inc. (LIXT) had Shareholders Equity of $0.83M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-3.59M |
|
-- |
|
-- |
|
$3.57M |
|
$-3.57M |
|
$-0.01M |
|
$-3.59M |
|
$-3.59M |
|
$-3.59M |
|
$-3.59M |
|
$-3.59M |
|
$-3.59M |
|
$-3.57M |
|
$-3.57M |
|
2.25M |
|
2.25M |
|
$-1.59 |
|
$-1.59 |
|
| Balance Sheet Financials | |
$1.15M |
|
-- |
|
-- |
|
$1.15M |
|
$0.32M |
|
-- |
|
-- |
|
$0.32M |
|
$-2.67M |
|
$0.83M |
|
|
Shareholders Equity |
$0.83M |
2.25M |
|
| Cash Flow Statement Financials | |
$-3.16M |
|
-- |
|
-- |
|
$4.20M |
|
$1.04M |
|
$-3.16M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.16M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
134.17% |
|
-433.50% |
|
-313.05% |
|
-433.50% |
|
$0.37 |
|
$-1.41 |
|
$-1.41 |
|